I Craig Henderson

Summary

Publications

  1. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
  2. ncbi request reprint Can we abandon anthracyclines for early breast cancer patients?
    I Craig Henderson
    Department of Medicine, University of California at San Francisco, USA
    Oncology (Williston Park) 25:115-24, 127. 2011
  3. ncbi request reprint Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
    I Craig Henderson
    Adjunct Professor of Medicine, University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Expert Rev Anticancer Ther 7:919-43. 2007
  4. ncbi request reprint Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer
    Beth Overmoyer
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106 5055, USA
    Clin Breast Cancer 6:150-7. 2005
  5. ncbi request reprint Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants
    Elizabeth B Lamont
    Department of Medicine and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA 02114, USA
    J Natl Cancer Inst 97:1080-3. 2005
  6. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
  7. ncbi request reprint Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)
    Elizabeth B Lamont
    Massachusetts General Hospital Cancer Center and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 98:1335-8. 2006
  8. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
  9. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
  10. pmc Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
    Cancer Treat Rev 34:223-30. 2008

Detail Information

Publications29

  1. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
  2. ncbi request reprint Can we abandon anthracyclines for early breast cancer patients?
    I Craig Henderson
    Department of Medicine, University of California at San Francisco, USA
    Oncology (Williston Park) 25:115-24, 127. 2011
    ..The results of these studies are provocative but insufficient to justify the conclusion that anthracyclines can be either abandoned or used only for a very select group of patients...
  3. ncbi request reprint Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
    I Craig Henderson
    Adjunct Professor of Medicine, University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Expert Rev Anticancer Ther 7:919-43. 2007
    ..Although it is not yet clear whether nab-paclitaxel can be routinely substituted for CrEL-paclitaxel or docetaxel in breast cancer treatment regimens, it seems highly likely that this will occur within the next 5 years...
  4. ncbi request reprint Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer
    Beth Overmoyer
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106 5055, USA
    Clin Breast Cancer 6:150-7. 2005
    ..Pegylated liposomal doxorubicin (PLD) is an active agent for breast cancer. The efficacy and safety of PLD in combination with cyclophosphamide as first-line treatment of metastatic breast cancer (MBC) was evaluated in this phase II study...
  5. ncbi request reprint Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants
    Elizabeth B Lamont
    Department of Medicine and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA 02114, USA
    J Natl Cancer Inst 97:1080-3. 2005
    ..Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer...
  6. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  7. ncbi request reprint Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)
    Elizabeth B Lamont
    Massachusetts General Hospital Cancer Center and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 98:1335-8. 2006
    ....
  8. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
    ..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
  9. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  10. pmc Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
    Cancer Treat Rev 34:223-30. 2008
    ..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
  11. doi request reprint Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants
    Elizabeth B Lamont
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Med Care 46:303-8. 2008
    ..Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly...
  12. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  13. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
    ....
  14. ncbi request reprint Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial
    Jennifer R Bellon
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 23:1934-40. 2005
    ..The optimal integration of chemotherapy with radiation (RT) for patients with early-stage breast cancer remains uncertain. We present the long-term results of a prospective randomized trial to address this question...
  15. ncbi request reprint Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer
    Hyman B Muss
    Fletcher Allen Health Care, Vermont Cancer Center, Burlington, VT 05401, USA
    JAMA 293:1073-81. 2005
    ....
  16. ncbi request reprint High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 20:743-50. 2002
    ..To assess survival of patients with metastatic breast cancer treated with high-dose chemotherapy (HDC) versus standard-dose chemotherapy (SDC)...
  17. ncbi request reprint Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B
    Raymond B Weiss
    Walter Reed Army Medical Center, Washington, DC, USA
    J Clin Oncol 21:1825-35. 2003
    ....
  18. ncbi request reprint Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 22:2061-8. 2004
    ..Cancer and Leukemia Group B Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infusion every 3 weeks to women with metastatic breast cancer...
  19. ncbi request reprint Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
    Alan M Keller
    US Oncology Inc, Cancer Care Associates, 6151 S Yale, Tulsa, OK 74136, USA
    J Clin Oncol 22:3893-901. 2004
    ..To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer...
  20. ncbi request reprint Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344
    Carolyn I Sartor
    Dept of Radiation Oncology, University of North Carolina School of Medicine, CB7512, Chapel Hill, NC 27599, USA
    J Clin Oncol 23:30-40. 2005
    ....
  21. ncbi request reprint The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
    Nicholas J Robert
    The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA
    Semin Oncol 31:106-46. 2004
    ..The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses...
  22. ncbi request reprint Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869
    Anthony J Guidi
    North Shore Medical Center, Salem, MA, USA
    J Clin Oncol 20:732-42. 2002
    ..However, the utility of this assay in node-positive patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) has not been well studied...
  23. pmc Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective
    Anjali S Kumar
    University of California, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Breast Cancer Res 7:271-5. 2005
    ..Treatment of DCIS with tamoxifen is still limited...
  24. ncbi request reprint Axillary surgery: clinical judgment required
    I Craig Henderson
    J Clin Oncol 24:325-6. 2006
  25. ncbi request reprint Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
    Kevin S Hughes
    Avon Comprehensive Breast Evaluation Center, Breast Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital, Division of Surgical Oncology, Boston 02114, USA
    N Engl J Med 351:971-7. 2004
    ..In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy...
  26. ncbi request reprint The evolving role of aromatase inhibitors in adjuvant breast cancer therapy
    I Craig Henderson
    Carol Franc Buck Breast Care Center, University of California San Francisco Comprehensive Cancer Center, 94143, USA
    Clin Breast Cancer 6:206-15. 2005
    ..In addition, case-based discussions are included to provide direction on how to integrate recent endocrine adjuvant clinical trial findings into everyday practice...
  27. ncbi request reprint Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole
    Robert W Carlson
    Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
    Breast Cancer Res Treat 80:S19-26; discussion S27-8. 2003
    ....
  28. ncbi request reprint A rose is no longer a rose
    I Craig Henderson
    J Clin Oncol 20:3365-8. 2002
  29. ncbi request reprint Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit
    I Craig Henderson
    University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA 94123, USA
    Semin Oncol 31:31-4. 2004
    ....